Compare Nano Dimension Ltd - ADR (NNDM) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nano Dimension Ltd - ADR vs Regeneron Pharmaceuticals Inc — how do they compare? Nano Dimension Ltd - ADR trades at $1.67 (market cap $350.49M), while Regeneron Pharmaceuticals Inc trades at $796.73 (market cap $82.06B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 234.1× Nano Dimension Ltd - ADR's market cap, and Regeneron Pharmaceuticals Inc pays a 0.47% dividend while Nano Dimension Ltd - ADR pays none. Which is the better fit depends on your goals.
| NNDM | REGN | |
|---|---|---|
Market Cap | $350.49M | $82.06B |
Sector | Technology | Health |
52-Week High | $2.14 | $812.27 |
52-Week Low | $1.21 | $555.51 |
Enterprise Value | -$54.35M | $76.77B |
Dividend Yield | — | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nano Dimension (NNDM) trades at $1.63, showing no change recently. The stock exhibits a bullish technical signal with strong moving average support, though RSI levels suggest overbought conditions. Fundamentally, the company reported revenue growth to $102.44M in 2025 but posted a significant net loss of $293.30M, reflecting ongoing profitability challenges. Recent strategic actions include cost-saving initiatives and the planned sale of MarkForged to Stratasys, aimed at reducing cash burn.
The outlook remains speculative due to persistent losses and cash flow concerns, despite potential from strategic divestitures. Investment opportunities hinge on successful execution of cost reductions and future profitability. Key risks include high cash burn, competitive pressures, and execution uncertainty amid leadership changes.
Regeneron Pharmaceuticals (REGN) trades at $808.05, up 3.02% today, with strong technical momentum and bullish moving averages. The company shows robust fundamentals: Q2 2026 EPS of $14.29 beat expectations by over 40%, revenue grew to $14.34B in 2025, and profit margins exceed 27%. However, RSI levels above 95 indicate overbought conditions, and the stock faces headwinds from multiple class-action lawsuits related to clinical trial disclosures.
Outlook remains positive due to earnings beats and product strength in Eylea HD and Dupixent, but legal overhangs and high valuation multiples pose near-term risks. Analysts maintain a Buy consensus with a $756.93 price target, suggesting cautious optimism amid legal scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nano Dimension Ltd - ADR
Nano Dimension Ltd is engaged in research and development of a three-dimensional printer that prints electronic circuit boards, also known as printed circuit boards, and ink materials and products based on nanotechnology. Its products consist of two main product lines - Dragonfly 2020 3D printer and proprietary ink products. The company's Dragonfly 2020 3D printer currently in development uses proprietary ink and integrated software to quickly create fully functioning PCB prototypes. Geographically, it generates maximum revenue from the USA followed by the Asia Pacific and Europe and Israel. It serves the Commercial, Research and Printing services industries.
Read more on NNDM →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
